Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled ALICE trial (NCT03164993, 24 May 2017) evaluated the addition of atezolizumab (anti-PD-L1) to immune-stimulating chemothera...

Повний опис

Збережено в:
Бібліографічні деталі
Автори: Andreas Hagen Røssevold, Nikolai Kragøe Andresen, Christina Bjerre, Bjørnar Gilje, Erik Jakobsen, Sunil Xavier Raj, Ragnhild Sørum Falk, Hege G. Russnes, Thea Jahr, Randi R. Mathiesen, Jon Lømo, Øystein Garred, Sudhir Kumar Chauhan, Ragnhild Reehorst Lereim, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Формат: Artigo
Мова:Англійська
Опубліковано: 2022
Онлайн доступ:https://doi.org/10.1038/s41591-022-02126-1
https://www.nature.com/articles/s41591-022-02126-1.pdf
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Інтернет

https://doi.org/10.1038/s41591-022-02126-1
https://www.nature.com/articles/s41591-022-02126-1.pdf

Схожі ресурси